Resource Summary Report

Generated by dkNET on Sep 3, 2026

YT

RRID:CVCL_1797
Type: Cell Line

Proper Citation

DSMZ Cat# ACC-434, RRID:CVCL_1797

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1797

Proper Citation: DSMZ Cat# ACC-434, RRID:CVCL_1797

Description: Cell line YT is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Natural killer cell lymphoblastic leukemia/lymphoma

Defining Citation: PMID:1313126, PMID:2578514, PMID:3098894, PMID:9787181, PMID:10803505, PMID:16408098, PMID:16827800, PMID:19194464, PMID:20164919, PMID:20454443, PMID:21052088, PMID:25586472, PMID:27397505, PMID:30894373, PMID:31160637, PMID:35839778

Comments: Population: Japanese., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: YT

Synonyms: YT-0

Cross References: BTO:BTO_0005228, CLO:CLO_0009718, EFO:EFO_0022423, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473541, Cell_Model_Passport:SIDM00410, ChEMBL-Cells:CHEMBL3308146, ChEMBL-Targets:CHEMBL2366114, Cosmic:850219, Cosmic:946358, Cosmic:991546, Cosmic:1012130, Cosmic:1524828, Cosmic:1542072, Cosmic:2390120, Cosmic:2785211, Cosmic-CLP:946358, DepMap:ACH-002317,

DSMZ:ACC-434, DSMZCellDive:ACC-434, EGA:EGAS00001000978, GDSC:946358, GEO:GSM236811, GEO:GSM236847, GEO:GSM472010, GEO:GSM1670588, IARC_TP53:27711, LINCS_LDP:LCL-1913, PharmacoDB:YT_1688_2019, PRIDE:PXD030304, PubChem_Cell_line:CVCL_1797, Wikidata:Q54995532

ID: CVCL_1797

Vendor: DSMZ

Catalog Number: ACC-434

Record Creation Time: 20220427T221739+0000

Record Last Update: 20260830T000422+0000

Ratings and Alerts

No rating or validation information has been found for YT.

No alerts have been found for YT.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Cancer research, 86(2), 295.

Calescibetta A, et al. (2026) Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. PloS one, 21(3), e0344471.

Wu J, et al. (2024) A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R? strengthens T cell-mediated anti-tumor therapies. Cell reports. Medicine, 5(10), 101747.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Kong Q, et al. (2023) Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. Science immunology, 8(82), eadg3196.

Huo J, et al. (2022) IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4. Investigational new drugs, 40(3), 537.

Gonçalves S, et al. (2021) COX2 regulates senescence secretome composition and senescence surveillance through PGE2. Cell reports, 34(11), 108860.